Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Receptors, Fibroblast Growth Factor
Receptor, Fibroblast Growth Factor, Type 3
Receptor, Fibroblast Growth Factor, Type 2
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Fibroblast Growth Factor 3